Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

17.12.21	FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA (PR Newswire)
06.12.21	Amgen Announces New Data Being Presented At ASH 2021 (PR Newswire)
03.12.21	Amgen Announces 10% Increase In 2022 First Quarter Dividend (PR Newswire)
02.12.21	Amgen : FDA Approves Kyprolis Combination Regimen For Multiple Myeloma Treatment (RTTNews)
01.12.21	Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis (PR Newswire)
01.12.21	FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent ... (PR Newswire)
29.11.21	Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year (PR Newswire)
29.11.21	Biotech Stocks Facing FDA Decision In December 2021 (RTTNews)
24.11.21	Amgen To Present At The 2021 Evercore ISI Healthcare Conference (PR Newswire)
24.11.21	Amgen To Present At The 2021 Piper Sandler Healthcare Conference (PR Newswire)
17.11.21	Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge (PR Newswire)
12.11.21	Amgen : Lumakras Gets Positive CHMP Opinion For Advanced Non-Small Cell Lung Cancer (RTTNews)
12.11.21	LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (PR Newswire)
10.11.21	Amgen To Present At The 2021 Annual Cowen IO Summit (PR Newswire)
08.11.21	First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia (PR Newswire)
05.11.21	Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio (PR Newswire)
02.11.21	Amgen Posts Promising FY Outlook After Narrower Profit In Q3 (RTTNews)
02.11.21	Amgen Inc. Q3 adjusted earnings Miss Estimates (RTTNews)
02.11.21	Amgen Reports Third Quarter 2021 Financial Results (PR Newswire)
28.10.21	Amgen Announces Webcast Of 2021 Third Quarter Financial Results (PR Newswire)
26.10.21	Fortune and Great Place to Work® Name Amgen One of the World's Best Workplaces™ in 2021 (PR Newswire)
21.10.21	Amgen Announces 2021 Fourth Quarter Dividend (PR Newswire)
19.10.21	Amgen Successfully Completes Acquisition Of Teneobio, Inc. (PR Newswire)
08.10.21	AstraZeneca: FDA Grants Orphan Drug Designation To Tezepelumab For Eosinophilic Esophagitis (RTTNews)
07.10.21	Amgen To Present Lumakras Combination Data From Phase 1b Study On KRAS G12C-mutated Cancers (RTTNews)
07.10.21	Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021 (PR Newswire)
07.10.21	Amgen, Neumora Collaborate To Advance Neuroscience Discovery - Quick Facts (RTTNews)
07.10.21	Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases (PR Newswire)
04.10.21	Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment (PR Newswire)
02.10.21	Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress (PR Newswire)
29.09.21	Amgen To Webcast Investor Call At EADV 2021 (PR Newswire)
25.09.21	FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia (PR Newswire)
22.09.21	Amgen To Present At The 2021 Cantor Global Healthcare Conference (PR Newswire)
22.09.21	Amgen Releases 8th Edition of Biosimilar Trends Report (PR Newswire)
21.09.21	Amgen Wins Patent Case on Otezla® (apremilast) (PR Newswire)
16.09.21	Amgen: LUMAKRAS With Vectibix Showed Encouraging Efficacy, Safety In KRAS G12C-Mutated CRC (RTTNews)
16.09.21	LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer (PR Newswire)
14.09.21	Zai Lab Reports Breakthrough Therapy Designation For Bemarituzumab In China (RTTNews)
13.09.21	Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference (PR Newswire)
13.09.21	Amgen To Webcast Investor Call At ESMO 2021 (PR Newswire)
13.09.21	Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021 (PR Newswire)
09.09.21	Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference (PR Newswire)
08.09.21	Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21 (PR Newswire)
05.09.21	Amgen's Tezepelumab Reduces Exacerbations In Patients With Severe Asthma & Comorbid Nasal Polyps (RTTNews)
05.09.21	New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps (PR Newswire)
03.09.21	Amgen to Present at the 16th Annual Citi BioPharma Conference (PR Newswire)
27.08.21	New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS) (PR Newswire)
03.08.21	Amgen Inc. Q2 adjusted earnings of $4.38 per share (RTTNews)
03.08.21	Amgen Reports Second Quarter 2021 Financial Results (PR Newswire)
30.07.21	Amgen Announces 2021 Third Quarter Dividend (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

26.11.24		Dow Jones aktuell: Dow Jones zum Handelsende in Grün
26.11.24		Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100
26.11.24		Börse New York: Dow Jones wenig verändert
26.11.24		Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu
26.11.24		Starker Wochentag in New York: S&P 500 präsentiert sich fester
26.11.24		Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester
26.11.24		Optimismus in New York: S&P 500 legt am Dienstagmittag zu
26.11.24		Pluszeichen in New York: NASDAQ Composite mittags in Grün

26.11.24

Dow Jones aktuell: Dow Jones zum Handelsende in Grün

26.11.24

Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100

26.11.24

Börse New York: Dow Jones wenig verändert

26.11.24

Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu

26.11.24

Starker Wochentag in New York: S&P 500 präsentiert sich fester

26.11.24

Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester